The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications
AbstractAlmost 600 million people are predicted to have diabetes mellitus (DM) by 2035. Diabetic patients suffer from increased rates of microvascular and macrovascular complications, associated with dyslipidaemia, impaired angiogenic responses to ischaemia, accelerated atherosclerosis, and inflammation. Despite recent treatment advances, many diabetic patients remain refractory to current approaches, highlighting the need for alternative agents. There is emerging evidence that high-density lipoproteins (HDL) are able to rescue diabetes-related vascular complications through diverse mechanisms. Such protective functions of HDL, however, can be rendered dysfunctional within the pathological milieu of DM, triggering the development of vascular complications. HDL-modifying therapies remain controversial as many have had limited benefits on cardiovascular risk, although more recent trials are showing promise. This review will discuss the latest data from epidemiological, clinical, and pre-clinical studies demonstrating various roles for HDL in diabetes and its vascular complications that have the potential to facilitate its successful translation. View Full-Text
Share & Cite This Article
Wong, N.K.P.; Nicholls, S.J.; Tan, J.T.M.; Bursill, C.A. The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. Int. J. Mol. Sci. 2018, 19, 1680.
Wong NKP, Nicholls SJ, Tan JTM, Bursill CA. The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. International Journal of Molecular Sciences. 2018; 19(6):1680.Chicago/Turabian Style
Wong, Nathan K.P.; Nicholls, Stephen J.; Tan, Joanne T.M.; Bursill, Christina A. 2018. "The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications." Int. J. Mol. Sci. 19, no. 6: 1680.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.